Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL pro Reporter Assay
Abstract
The COVID-19 pandemic has already led to more than 700,000 deaths and innumerable changes to daily life worldwide. Along with development of a vaccine, identification of effective antivirals to treat infected patients is of the highest importance. However, rapid drug discovery requires efficient methods to identify novel compounds that can inhibit the virus. In this work, we present a method for identifying inhibitors of the SARS-CoV-2 main protease, 3CL pro . This reporter-based assay allows for antiviral drug screening in human cell culture at biosafety level 2 (BSL2) with high-throughput compatible sample processing and analysis. This assay may help identify novel antivirals to control the COVID-19 pandemic.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 27, 2020
- Source ID
- 10.1128/jvi.01265-20
Entities
People
- Brook E. Heaton
- Heather M. Froggatt
- Nicholas S Heaton
Organizations
- Duke University